Compound: zolmitriptan
SMILES: O=C1OC[C@@H](N1)Cc2cc3c([nH]cc3CCN(C)C)cc2
InChIKey: ULSDMUVEXKOYBU-ZDUSSCGKSA-N
Synonyms: zolmitriptan, 139264-17-8, Zomig, Zomigoro, Zomig-ZMT, 311C90, AscoTop, zolmitriptanum, Cvt-427, 2FS66TH3YW, NSC-760383, (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one, DTXSID8045933, 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone, (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone, DTXCID6025933, CHEBI:10124, 311-C-90, 2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)-, (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one, 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one, (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one, Zolmiptriptan, Zolmitriptan OD, 4-((3-(2-dimethylaminoethyl)-1H-indol-5-yl)methyl)oxazolidin-2-one, (4S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-1,3-oxazolidin-2-one, (4S)-4-((3-(2-dimethylaminoethyl)-1H-indol-5-yl)methyl)-1,3-oxazolidin-2-one, (S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-1,3-oxazolidin-2-one, (S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one, RefChem:57200, N02CC03, 2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-,(S)-, 629-919-0, Zomigon, Flezol, (S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)oxazolidin-2-one, BW-311C90, MFCD00871503, (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one, 2-Oxazolidinone, 4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-, (4S)-, CHEMBL1185, Zomig Nasal Spray, Zomig ZMT, AscoTopand, Zolmitriptan [USAN], (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone, (4S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl-2-oxazolidinone, (4S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, zipton, zolmitriptane, zominat, Rapimelt, SMR000449310, CAS-139264-17-8, Zomig (TN), Zolmitriptan RapidFilm, UNII-2FS66TH3YW, s1649, Zolmitriptan [USAN:INN:BAN], (S)-4-({3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl}methyl)oxazolidin-2-one, (S)-4-[[3-[2-(Dimethylamino)ethyl]indol-5-yl]methyl]-2-oxazolidinone, Zolmitriptan CRS, NCGC00095155-01, Zolmitriptan (Zomig), KS-5072, Spectrum2_000728, ZOLMITRIPTAN [MI], ZOLMITRIPTAN [INN], ZOLMITRIPTAN [JAN], GTPL60, ZOLMITRIPTAN [VANDF], SCHEMBL33336, ZOLMITRIPTAN [MART.], MLS000758208, MLS001424172, BIDD:GT0040, SPECTRUM1505281, ZOLMITRIPTAN [USP-RS], ZOLMITRIPTAN [WHO-DD], SPBio_000656, Zolmitriptan (JAN/USP/INN), orb1309803, SCHEMBL29356689, Zolmitriptan - Bio-X trade mark, Zolmitriptan, >=98% (HPLC), GLXC-05182, HMS1922B04, HMS2052K17, HMS2093O14, HMS2235I22, HMS3714H11, HMS3884A06, Pharmakon1600-01505281, ZOLMITRIPTAN [ORANGE BOOK], ZOLMITRIPTAN [EP MONOGRAPH], HY-B0229, Tox21_111455, ZOLMITRIPTAN [USP MONOGRAPH], BDBM50033383, CCG-38993, EBC-26462, HB1801, MSK168257, NSC760383, (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]oxazolidin-2-one, (S)-4-[[3-[2-(Dimethylamino)ethyl]-5-indolyl]methyl]oxazolidin-2-one, AKOS015850706, Tox21_111455_1, DB00315, FZ28774, NC00382, NSC 760383, (S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl]ethylamine, NCGC00263884-02, NCGC00263884-03, NCGC00263884-08, BZ164590, SY057937, BW-311C90;311C90, SBI-0206762.P001, SW197762-2, Z0024, C07218, D00415, AB00698244-05, AB00698244_06, EN300-18567396, Q218820, SR-05000001693, SR-05000001693-1, BRD-K54314721-001-09-4, BRD-K54314721-001-10-2, Zolmitriptan, United States Pharmacopeia (USP) Reference Standard, (s)-4-{3-[2-(dimethylamino)ethyl]-1h-indol-5-ylmethyl}oxazolidin-2-one, (S) -N,N-Dimethyl-2- [5- (2-oxo-1,3-oxazolidin-4-ylmethyl) -1H -indol-3-yl]ethylamine, (S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H -indol-3-yl]ethylamine, 139264-25-8
Theoretical properties:
molecular_formula: C16H21N3O2
molecular_weight: 287.36 g/mol
exact_mass: 287.16337692 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 5
heavy_atom_count: 21
topological_polar_surface_area: 57.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Zolmitriptan is a member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine. It has a role as an anti-inflammatory drug, a serotonergic agonist and a vasoconstrictor agent. It is a member of tryptamines and an oxazolidinone. It is functionally related to a N,N-dimethyltryptamine.
chebi: A member of the class of tryptamines that is <em>N</em>,<em>N</em>-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4<i>S</i>)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.
chembl: ZOLMITRIPTAN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Zolmitriptan, sold under the brand name Zomig among others, is a serotonergic medication which is used in the acute treatment of migraine attacks with or without aura and cluster headaches. It is taken by mouth as a swallowed or disintegrating tablet or as a nasal spray.
Side effects include tightness in the neck or throat, jaw pain, dizziness, paresthesia, asthenia, somnolence, warm/cold sensations, nausea, chest pressure, and dry mouth. The drug acts as a selective serotonin 5-HT1B and 5-HT1D receptor agonist. Structurally, it is a triptan and a tryptamine derivative.
It was patented in 1990 and was approved for medical use in 1997.